Baidu
map

Celltrion的单克隆抗体药物瑞丹维单抗获欧盟委员会批准用于治疗新冠肺炎

2021-11-17 国际文传 网络

根据欧洲药品管理局(EMA)人用药品委员会(CHMP)上周(2021年11月11日)出具的肯定意见,欧盟委员会(EC)批准了Celltrion有关瑞丹维单抗的上市申请。

Celltrion集团今天宣布,欧盟委员会(EC)已批准Regkirona(瑞丹维单抗,CT-P59)的上市申请。瑞丹维单抗是欧洲药品管理局(EMA)核准上市的首批单抗药之一。EC批准瑞丹维单抗用于治疗无需输氧但有较高风险转为重症的新冠肺炎成人患者。EC的这一决定基于欧洲药品管理局(EMA)人用药品委员会(CHMP)于2021年11月11日出具的肯定意见。1

Celltrion Healthcare医疗和营销部门负责人HoUng Kim博士表示:“今天的成就,加上CHMP对瑞丹维单抗的肯定意见,凸显出我们致力于解决世界上重大健康挑战的持续承诺。通常情况下,从CHMP的建议提交给欧盟委员会,到其快速做出具有法律约束力的决定,整个过程需要一到两个月时间。然而,鉴于疫情这一特殊时期,我们当天就获得了EC的批准。为了加快瑞丹维单抗的全球供应,我们一直在与位于欧洲、亚洲和拉丁美洲的30个国家的政府和经销商进行沟通。我们将继续与所有主要利益相关者合作,确保世界各地的新冠肺炎患者均可获得安全有效的治疗。”

单克隆抗体是能够附着在特定靶标上的蛋白质,对瑞丹维单抗来说,靶标是SARS-CoV-2的棘突蛋白,附着之后,抗体能够阻断病毒进入人体细胞。本次EC核准基于一项全球III期临床试验,该试验在包括美国、西班牙和罗马尼亚在内的13个国家招募了超过1,315例患者,以评价瑞丹维单抗的有效性和安全性。数据显示,对于有较大可能转为重症的高风险新冠患者,瑞丹维单抗可显著降低新冠肺炎相关的住院或死亡风险,降低幅度高达72%。

目前,瑞丹维单抗在印度尼西亚和巴西已获得紧急使用许可,在韩国已获得完全批准。在美国,瑞丹维单抗尚未获得美国食品药品监督管理局(FDA)批准,但公司正在与FDA讨论紧急使用授权(EUA)申请等事项。

截至2021年11月12日,韩国129家医院已有超过22,587例患者接受瑞丹维单抗治疗。

 

关于瑞丹维单抗(CT-P59)

通过筛选候选抗体并选择中和SARS-CoV-2病毒效价最高的抗体,确定CT-P59为新冠肺炎的潜在治疗药物。体外体内临床前研究显示,CT-P59可强力结合SARS-CoV-2 RBD,显著中和受到关注的野生型和突变型变异株。在体内模型中,CT-P59可有效降低SARS-CoV-2的病毒载量和肺部炎症。全球I期和II/III期临床试验结果显示,CT-P59对轻度至中度新冠肺炎症状患者具有良好的安全性、耐受性、抗病毒效应和有效性2。Celltrion最近同时开始开发一种中和抗体鸡尾酒合剂,用CT-P59对抗新出现的SARS-CoV-2变异株。

 

参考文献

1欧洲药品管理局。新冠肺炎:EMA建议批准两种单克隆抗体药物。网址:https://www.ema.europa.eu/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines [最后访问时间:2021年11月]。
2 Celltrion存档数据

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1962632, encodeId=4afa19626328f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 04 21:17:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957647, encodeId=c7ae195e647ad, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Feb 03 08:17:47 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872313, encodeId=f25e18e231378, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 06 23:17:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782786, encodeId=b88f1e8278604, content=<a href='/topic/show?id=f0dc44e363' target=_blank style='color:#2F92EE;'>#Celltrion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4473, encryptionId=f0dc44e363, topicName=Celltrion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 30 03:17:47 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016195, encodeId=1d842016195a5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 02 17:17:47 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660267, encodeId=5070166026e7e, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Oct 12 16:17:47 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796479, encodeId=247f1e96479cd, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Mon Jan 24 22:17:47 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627691, encodeId=1cd8162e6912e, content=<a href='/topic/show?id=6e8c63116d3' target=_blank style='color:#2F92EE;'>#欧盟委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63116, encryptionId=6e8c63116d3, topicName=欧盟委员会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4df621126020, createdName=wangtianj2014@, createdTime=Fri Nov 19 06:17:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071275, encodeId=cd4c10e127577, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:31 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
    2021-12-04 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1962632, encodeId=4afa19626328f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 04 21:17:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957647, encodeId=c7ae195e647ad, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Feb 03 08:17:47 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872313, encodeId=f25e18e231378, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 06 23:17:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782786, encodeId=b88f1e8278604, content=<a href='/topic/show?id=f0dc44e363' target=_blank style='color:#2F92EE;'>#Celltrion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4473, encryptionId=f0dc44e363, topicName=Celltrion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 30 03:17:47 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016195, encodeId=1d842016195a5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 02 17:17:47 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660267, encodeId=5070166026e7e, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Oct 12 16:17:47 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796479, encodeId=247f1e96479cd, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Mon Jan 24 22:17:47 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627691, encodeId=1cd8162e6912e, content=<a href='/topic/show?id=6e8c63116d3' target=_blank style='color:#2F92EE;'>#欧盟委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63116, encryptionId=6e8c63116d3, topicName=欧盟委员会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4df621126020, createdName=wangtianj2014@, createdTime=Fri Nov 19 06:17:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071275, encodeId=cd4c10e127577, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:31 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1962632, encodeId=4afa19626328f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 04 21:17:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957647, encodeId=c7ae195e647ad, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Feb 03 08:17:47 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872313, encodeId=f25e18e231378, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 06 23:17:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782786, encodeId=b88f1e8278604, content=<a href='/topic/show?id=f0dc44e363' target=_blank style='color:#2F92EE;'>#Celltrion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4473, encryptionId=f0dc44e363, topicName=Celltrion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 30 03:17:47 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016195, encodeId=1d842016195a5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 02 17:17:47 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660267, encodeId=5070166026e7e, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Oct 12 16:17:47 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796479, encodeId=247f1e96479cd, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Mon Jan 24 22:17:47 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627691, encodeId=1cd8162e6912e, content=<a href='/topic/show?id=6e8c63116d3' target=_blank style='color:#2F92EE;'>#欧盟委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63116, encryptionId=6e8c63116d3, topicName=欧盟委员会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4df621126020, createdName=wangtianj2014@, createdTime=Fri Nov 19 06:17:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071275, encodeId=cd4c10e127577, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:31 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1962632, encodeId=4afa19626328f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 04 21:17:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957647, encodeId=c7ae195e647ad, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Feb 03 08:17:47 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872313, encodeId=f25e18e231378, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 06 23:17:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782786, encodeId=b88f1e8278604, content=<a href='/topic/show?id=f0dc44e363' target=_blank style='color:#2F92EE;'>#Celltrion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4473, encryptionId=f0dc44e363, topicName=Celltrion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 30 03:17:47 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016195, encodeId=1d842016195a5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 02 17:17:47 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660267, encodeId=5070166026e7e, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Oct 12 16:17:47 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796479, encodeId=247f1e96479cd, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Mon Jan 24 22:17:47 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627691, encodeId=1cd8162e6912e, content=<a href='/topic/show?id=6e8c63116d3' target=_blank style='color:#2F92EE;'>#欧盟委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63116, encryptionId=6e8c63116d3, topicName=欧盟委员会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4df621126020, createdName=wangtianj2014@, createdTime=Fri Nov 19 06:17:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071275, encodeId=cd4c10e127577, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:31 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1962632, encodeId=4afa19626328f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 04 21:17:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957647, encodeId=c7ae195e647ad, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Feb 03 08:17:47 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872313, encodeId=f25e18e231378, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 06 23:17:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782786, encodeId=b88f1e8278604, content=<a href='/topic/show?id=f0dc44e363' target=_blank style='color:#2F92EE;'>#Celltrion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4473, encryptionId=f0dc44e363, topicName=Celltrion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 30 03:17:47 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016195, encodeId=1d842016195a5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 02 17:17:47 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660267, encodeId=5070166026e7e, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Oct 12 16:17:47 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796479, encodeId=247f1e96479cd, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Mon Jan 24 22:17:47 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627691, encodeId=1cd8162e6912e, content=<a href='/topic/show?id=6e8c63116d3' target=_blank style='color:#2F92EE;'>#欧盟委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63116, encryptionId=6e8c63116d3, topicName=欧盟委员会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4df621126020, createdName=wangtianj2014@, createdTime=Fri Nov 19 06:17:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071275, encodeId=cd4c10e127577, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:31 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1962632, encodeId=4afa19626328f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 04 21:17:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957647, encodeId=c7ae195e647ad, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Feb 03 08:17:47 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872313, encodeId=f25e18e231378, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 06 23:17:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782786, encodeId=b88f1e8278604, content=<a href='/topic/show?id=f0dc44e363' target=_blank style='color:#2F92EE;'>#Celltrion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4473, encryptionId=f0dc44e363, topicName=Celltrion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 30 03:17:47 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016195, encodeId=1d842016195a5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 02 17:17:47 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660267, encodeId=5070166026e7e, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Oct 12 16:17:47 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796479, encodeId=247f1e96479cd, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Mon Jan 24 22:17:47 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627691, encodeId=1cd8162e6912e, content=<a href='/topic/show?id=6e8c63116d3' target=_blank style='color:#2F92EE;'>#欧盟委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63116, encryptionId=6e8c63116d3, topicName=欧盟委员会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4df621126020, createdName=wangtianj2014@, createdTime=Fri Nov 19 06:17:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071275, encodeId=cd4c10e127577, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:31 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
    2022-10-12 aids221
  7. [GetPortalCommentsPageByObjectIdResponse(id=1962632, encodeId=4afa19626328f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 04 21:17:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957647, encodeId=c7ae195e647ad, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Feb 03 08:17:47 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872313, encodeId=f25e18e231378, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 06 23:17:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782786, encodeId=b88f1e8278604, content=<a href='/topic/show?id=f0dc44e363' target=_blank style='color:#2F92EE;'>#Celltrion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4473, encryptionId=f0dc44e363, topicName=Celltrion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 30 03:17:47 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016195, encodeId=1d842016195a5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 02 17:17:47 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660267, encodeId=5070166026e7e, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Oct 12 16:17:47 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796479, encodeId=247f1e96479cd, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Mon Jan 24 22:17:47 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627691, encodeId=1cd8162e6912e, content=<a href='/topic/show?id=6e8c63116d3' target=_blank style='color:#2F92EE;'>#欧盟委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63116, encryptionId=6e8c63116d3, topicName=欧盟委员会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4df621126020, createdName=wangtianj2014@, createdTime=Fri Nov 19 06:17:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071275, encodeId=cd4c10e127577, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:31 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1962632, encodeId=4afa19626328f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 04 21:17:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957647, encodeId=c7ae195e647ad, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Feb 03 08:17:47 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872313, encodeId=f25e18e231378, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 06 23:17:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782786, encodeId=b88f1e8278604, content=<a href='/topic/show?id=f0dc44e363' target=_blank style='color:#2F92EE;'>#Celltrion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4473, encryptionId=f0dc44e363, topicName=Celltrion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 30 03:17:47 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016195, encodeId=1d842016195a5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 02 17:17:47 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660267, encodeId=5070166026e7e, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Oct 12 16:17:47 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796479, encodeId=247f1e96479cd, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Mon Jan 24 22:17:47 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627691, encodeId=1cd8162e6912e, content=<a href='/topic/show?id=6e8c63116d3' target=_blank style='color:#2F92EE;'>#欧盟委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63116, encryptionId=6e8c63116d3, topicName=欧盟委员会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4df621126020, createdName=wangtianj2014@, createdTime=Fri Nov 19 06:17:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071275, encodeId=cd4c10e127577, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:31 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1962632, encodeId=4afa19626328f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Dec 04 21:17:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957647, encodeId=c7ae195e647ad, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Thu Feb 03 08:17:47 CST 2022, time=2022-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1872313, encodeId=f25e18e231378, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Aug 06 23:17:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782786, encodeId=b88f1e8278604, content=<a href='/topic/show?id=f0dc44e363' target=_blank style='color:#2F92EE;'>#Celltrion#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4473, encryptionId=f0dc44e363, topicName=Celltrion)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 30 03:17:47 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016195, encodeId=1d842016195a5, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Jul 02 17:17:47 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660267, encodeId=5070166026e7e, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Oct 12 16:17:47 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796479, encodeId=247f1e96479cd, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17827, encryptionId=c6051e82765, topicName=Trio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Mon Jan 24 22:17:47 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627691, encodeId=1cd8162e6912e, content=<a href='/topic/show?id=6e8c63116d3' target=_blank style='color:#2F92EE;'>#欧盟委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63116, encryptionId=6e8c63116d3, topicName=欧盟委员会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4df621126020, createdName=wangtianj2014@, createdTime=Fri Nov 19 06:17:47 CST 2021, time=2021-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071275, encodeId=cd4c10e127577, content=症和危重症病人达到78,740例;全球新, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Nov 18 08:03:31 CST 2021, time=2021-11-18, status=1, ipAttribution=)]
    2021-11-18 查查佳佳

    症和危重症病人达到78,740例;全球新

    0

相关资讯

Cancer Cell:新型单克隆抗体药物或可有效克服白血病的耐药性

近日,刊登在国际杂志Cancer Cell上的一篇研究论文中,来自英国南安普敦大学的研究人员通过研究开发了一种新型药物,其或可癌症对免疫疗法的耐受性,该药物在临床前模型中表现出了较大潜力,而且研究者希望其可以在后期应用于治疗特定的白血病及非霍奇金淋巴瘤患者。 近些年来,由单克隆抗体制造的靶向药物在治疗许多癌症上带来了革命性的成效,其通过吸附在癌细胞表面上的特殊蛋白对癌细胞进行标记,进而由机体

拓展阅读

JAMA子刊:新冠肺炎感染是否增加青少年2型糖尿病发病风险?

在10至19岁青少年群体中,COVID-19感染与T2D的发生存在显著关联,尤其在肥胖和住院患者中风险更高。

Hip Pelvis:新冠肺炎疫情对髋部骨折患者康复的影响

大流行疫情对住院护理医院的老年髋部骨折患者术后活动的恢复有不利影响,在完全限制家属进入以防止感染的情况下。

Critical Care Medicine:巴瑞替尼与c治疗重症新冠肺炎的疗效与不良反应

我们对重症新冠肺炎住院患者进行的倾向性得分匹配的回顾性观察研究显示,与托珠单抗相比,巴瑞替尼的病死率没有差异,但不良反应显著减少。

Critical Care Medicine:肾素-血管紧张素系统途径疗法与改善新冠肺炎男性住院患者预后相关

男性使用ARB与较低的机械通气和血管活性药物的使用率有关,而在女性中没有观察到该现象。RAS系统失调的性别差异可能导致COVID-19患者预后和对ARB药物反应性的性别差异。

2023年度巨献:中国中药领域十大医学研究出炉

2023年梅斯年终巨献:中国重磅级医学研究成果解读!

重磅!钟南山团队最新发表,连花清瘟的双盲、随机对照临床试验的结果出炉!

《病毒学》:与对照组相比,连花清瘟能够加速缓解多种临床症状,包括鼻塞、喉咙痛、咳嗽、发烧等等,从而促进轻至中度新冠肺炎患者的恢复。且两组安全性相当。

2024 WHO:药物信息

世界卫生组织(WHO,The World Health Organization) · 2024-12-02

M12药物相互作用研究

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2024-07-31

《M12:药物相互作用》-英文版

国家药品监督管理局药品审评中心(CDE) · 2024-07-17

《M12:药物相互作用》-中文版

国家药品监督管理局药品审评中心(CDE) · 2024-07-17

2024 FDA指南:药物开发平台技术指定项目

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2024-05-29

Baidu
map
Baidu
map
Baidu
map